{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:42:31Z","timestamp":1791175351309,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cell & Developmental Biology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.semcdb.2010.08.007","type":"journal-article","created":{"date-parts":[[2010,9,3]],"date-time":"2010-09-03T10:03:21Z","timestamp":1283508201000},"page":"944-950","source":"Crossref","is-referenced-by-count":131,"title":["The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics"],"prefix":"10.1016","volume":"21","author":[{"given":"Dhara N.","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia R.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Moasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcdb.2010.08.007_bib0005","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor","volume":"125","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0010","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0015","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/j.1460-2075.1996.tb00603.x","article-title":"Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions","volume":"15","author":"Pinkas-Kramarski","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0020","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.91.17.8132","article-title":"Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity","volume":"91","author":"Guy","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1042\/bj3220757","article-title":"Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein","volume":"322","author":"Sierke","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0030","doi-asserted-by":"crossref","first-page":"21608","DOI":"10.1073\/pnas.0912101106","article-title":"Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3","volume":"106","author":"Jura","year":"2009","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0035","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/MCB.14.6.3550","article-title":"ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor","volume":"14","author":"Soltoff","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0040","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/j.1460-2075.1994.tb06577.x","article-title":"Identification of c-erbB-3 binding sites for phosphatidylinositol 3\u2032-kinase and SHC using an EGF receptor\/c-erbB-3 chimera","volume":"13","author":"Prigent","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1128\/MCB.14.1.492","article-title":"Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB\/EGFR family members","volume":"14","author":"Fedi","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0050","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1074\/jbc.275.12.8641","article-title":"A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis","volume":"275","author":"Kainulainen","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0055","series-title":"ErbB3\/HER3 does not homodimerize upon neuregulin binding at the cell surface","author":"Berger","year":"2004"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0060","series-title":"Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin","author":"Kani","year":"2005"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2009.04.011","article-title":"The upgraded role of HER3 and HER4 receptors in breast cancer","volume":"74","author":"Koutras","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0070","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer","volume":"200","author":"Witton","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0075","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1158\/1078-0432.CCR-04-1633","article-title":"Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast","volume":"11","author":"Barnes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0080","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nature04177","article-title":"A quantitative protein interaction network for the ErbB receptors using protein microarrays","volume":"439","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0085","doi-asserted-by":"crossref","first-page":"2005.0008","DOI":"10.1038\/msb4100012","article-title":"Phosphotyrosine interactome of the ErbB-receptor kinase family","volume":"1","author":"Schulze","year":"2005","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0065-230X(05)94002-5","article-title":"Activation of AKT kinases in cancer: implications for therapeutic targeting","volume":"94","author":"Bellacosa","year":"2005","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","article-title":"The two TORCs and Akt","volume":"12","author":"Bhaskar","year":"2007","journal-title":"Dev Cell"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A complex interplay between Akt, TSC2 and the two mTOR complexes","volume":"37","author":"Huang","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0105","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1074\/jbc.271.7.3884","article-title":"Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2","volume":"271","author":"Zhang","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0110","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/ijc.22257","article-title":"ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas","volume":"119","author":"Jeong","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0115","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.1158\/0008-5472.CAN-05-1855","article-title":"Somatic mutations of the protein kinase gene family in human lung cancer","volume":"65","author":"Davies","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/bcr1843","article-title":"Cytogenetic analysis of HER1\/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients","volume":"10","author":"Sassen","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0125","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0130","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","article-title":"A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy","volume":"68","author":"Lee-Hoeflich","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0135","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/bjc.1998.689","article-title":"Expression of c-erbB3 protein in primary breast carcinomas","volume":"78","author":"Naidu","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0140","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ijc.21358","article-title":"Akt is frequently activated in HER2\/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients","volume":"118","author":"Tokunaga","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0145","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/1078-0432.CCR-04-0112","article-title":"Activation of the Akt\/mammalian target of rapamycin\/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers","volume":"10","author":"Zhou","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0150","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.11273","article-title":"Prognostic value of ERBB family mRNA expression in breast carcinomas","volume":"106","author":"Bieche","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0155","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.biocel.2006.11.017","article-title":"Breast cancer: the upgraded role of HER-3 and HER-4","volume":"39","author":"Karamouzis","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0160","first-page":"4217","article-title":"Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay","volume":"6","author":"Pawlowski","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/bjc.1996.342","article-title":"C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators","volume":"74","author":"Travis","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0170","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-08-0186","article-title":"HER3 is a determinant for poor prognosis in melanoma","volume":"14","author":"Reschke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1755-148X.2009.00616.x","article-title":"NRG1\/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation","volume":"22","author":"Buac","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0180","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.cmr.0000130874.33504.2f","article-title":"Her2\/neu is not a commonly expressed therapeutic target in melanoma\u2014a large cohort tissue microarray study","volume":"14","author":"Kluger","year":"2004","journal-title":"Melanoma Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0185","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ijc.23465","article-title":"Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells","volume":"123","author":"Ueno","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0190","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.438","article-title":"Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4","volume":"41","author":"Prickett","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0195","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/ijc.24651","article-title":"HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells","volume":"125","author":"Soler","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0200","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.88.17.7792","article-title":"Differential expression of epidermal growth factor-related proteins in human colorectal tumors","volume":"88","author":"Ciardiello","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/path.1711700309","article-title":"Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1","volume":"170","author":"Rajkumar","year":"1993","journal-title":"J Pathol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0210","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0046-8177(98)90444-0","article-title":"Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2","volume":"29","author":"Maurer","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0215","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2407-6-46","article-title":"Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas","volume":"6","author":"Kountourakis","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0220","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s004320050034","article-title":"Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival","volume":"126","author":"Kapitanovic","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0225","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI36435","article-title":"Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium","volume":"119","author":"Lee","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0230","doi-asserted-by":"crossref","first-page":"11478","DOI":"10.1158\/0008-5472.CAN-05-1977","article-title":"High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor","volume":"65","author":"Fujimoto","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.lungcan.2008.03.011","article-title":"Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients","volume":"62","author":"Reinmuth","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0240","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1158\/1078-0432.CCR-08-2549","article-title":"Analysis of ErbB receptors in pulmonary carcinoid tumors","volume":"15","author":"Rickman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0245","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1158\/1078-0432.CCR-08-2921","article-title":"HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors","volume":"15","author":"Sun","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0250","first-page":"142","article-title":"High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas","volume":"10","author":"Yi","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0255","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0260","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0265","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1073\/pnas.0409773102","article-title":"ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines","volume":"102","author":"Engelman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0270","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0275","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0280","first-page":"568","article-title":"Relationship of expression of C-erbB2, C-erbB3, and C-erbB4 with ovarian carcinoma","volume":"23","author":"Li","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0285","first-page":"3933","article-title":"Neuregulin expression, function, and signaling in human ovarian cancer cells","volume":"8","author":"Gilmour","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0290","doi-asserted-by":"crossref","first-page":"M199","DOI":"10.1136\/mp.49.4.M199","article-title":"c-erbB3 protein expression in ovarian cancer","volume":"49","author":"Rajkumar","year":"1996","journal-title":"Clin Mol Pathol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0295","first-page":"67","article-title":"Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary","volume":"12","author":"Leng","year":"1997","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0300","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ijc.2910640310","article-title":"c-erbB growth-factor-receptor proteins in ovarian tumours","volume":"64","author":"Simpson","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0305","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/bjc.1995.147","article-title":"c-erbB-3 protein expression in ovarian tumours","volume":"71","author":"Simpson","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0310","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2005.04.8397","article-title":"ErbB-3 predicts survival in ovarian cancer","volume":"24","author":"Tanner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0315","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ccr.2009.12.047","article-title":"An activated ErbB3\/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells","volume":"17","author":"Sheng","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0320","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.jnen.0000229989.25171.aa","article-title":"Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma","volume":"65","author":"Addo-Yobo","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0325","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/glia.20197","article-title":"Neuregulin-1 enhances survival of human astrocytic glioma cells","volume":"51","author":"Ritch","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0330","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/nen.0b013e3181257190","article-title":"Unique molecular characteristics of radiation-induced glioblastoma","volume":"66","author":"Donson","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0465","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0340","first-page":"78","article-title":"Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"26","author":"Baselga","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0345","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0350","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0355","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1038\/onc.2008.13","article-title":"Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2\/neu and the EGFR-p185her2\/neu complexes","volume":"27","author":"Cai","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0360","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1158\/1078-0432.CCR-08-2814","article-title":"Suppression of HER2\/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab","volume":"15","author":"Yao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0365","first-page":"971","article-title":"Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B","volume":"2","author":"Fuino","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0370","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0375","first-page":"1175","article-title":"Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein","volume":"4","author":"Weiner","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0380","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","article-title":"Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens","volume":"20","author":"Blackwell","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0385","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","article-title":"A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer","volume":"19","author":"Burstein","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0390","series-title":"San Antonio Breast Cancer Symposium","article-title":"Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer","author":"Burstein","year":"2008"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0395","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(09)70087-7","article-title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study","volume":"10","author":"Kaufman","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0400","doi-asserted-by":"crossref","first-page":"#10562","DOI":"10.1200\/jco.2007.25.18_suppl.10562","article-title":"Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer","volume":"25","author":"Gomez","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0405","series-title":"San Antonio Breast Cancer Symposium","first-page":"#1091","article-title":"Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer","author":"Iwata","year":"2006"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0410","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.semcdb.2010.08.007_bib0415","doi-asserted-by":"crossref","first-page":"ra7","DOI":"10.1126\/scitranslmed.3000389","article-title":"Resiliency and vulnerability in the HER2\u2013HER3 tumorigenic driver","volume":"2","author":"Amin","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0420","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/0008-5472.CAN-06-2980","article-title":"The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function","volume":"67","author":"Folgiero","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0425","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1128\/MCB.01245-06","article-title":"Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1","volume":"27","author":"Cao","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0430","doi-asserted-by":"crossref","first-page":"11279","DOI":"10.1158\/0008-5472.CAN-06-2319","article-title":"Loss of Nrdp1 enhances ErbB2\/ErbB3-dependent breast tumor cell growth","volume":"66","author":"Yen","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0435","doi-asserted-by":"crossref","first-page":"47050","DOI":"10.1074\/jbc.M409703200","article-title":"The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases","volume":"279","author":"Laederich","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0440","doi-asserted-by":"crossref","first-page":"8286","DOI":"10.1158\/0008-5472.CAN-07-6316","article-title":"Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer","volume":"68","author":"Miller","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0445","doi-asserted-by":"crossref","first-page":"19310","DOI":"10.1074\/jbc.M603225200","article-title":"The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3","volume":"281","author":"Funes","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0450","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/0008-5472.CAN-08-2920","article-title":"microRNA-205 regulates HER3 in human breast cancer","volume":"69","author":"Iorio","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0455","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1172\/JCI28656","article-title":"Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer","volume":"116","author":"Engelman","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semcdb.2010.08.007_bib0460","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"}],"container-title":["Seminars in Cell & Developmental Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952110001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952110001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T06:11:22Z","timestamp":1591855882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1084952110001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1084952110001448"],"URL":"https:\/\/doi.org\/10.1016\/j.semcdb.2010.08.007","relation":{},"ISSN":["1084-9521"],"issn-type":[{"value":"1084-9521","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}